Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: J Thorac Oncol. 2017 Aug 10;12(11):1696–1703. doi: 10.1016/j.jtho.2017.07.030

Figure 2.

Figure 2

Overall survival (OS) in patients with metachronous second malignancies (MSM) and in patients with no other malignancies and without recurrence of limited-stage small cell lung cancer (LSCLC No Recur). OS was better among patients with MSM (log-rank P=0.0302).